RESUMO
In this double-blind trial in 60 recreational athletes suffering from Achilles peritendinitis, we compared the effect of local injections of glycosaminoglycan polysulfate (GAGPS) with oral indomethacin (IM) administered over a 2-week period. Orthotic devices were prescribed in 66% of the cases to control biomechanical errors. The results after 1-year follow-up showed that GAGPS had a good overall therapeutic effect on two-thirds of the patients compared to one-third of the IM treated. In the patients with symptoms lasting longer than 3 months, IM had an effect in only 12% while GAGPS was beneficial in 59%. Twenty-five cases of non-responders and relapses underwent a crossover treatment. Those who received IM in this second period did not benefit from this treatment while those who received GAGPS showed a moderate to good effect in 8/17 (47%) after a 2-week follow-up. A different mode of action is suggested as an explanation of the encouraging results.
Assuntos
Tendão do Calcâneo , Glicosaminoglicanos/uso terapêutico , Indometacina/administração & dosagem , Tendinopatia/tratamento farmacológico , Administração Oral , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Humanos , Indometacina/uso terapêutico , Injeções Intramusculares , Masculino , Pessoa de Meia-Idade , Distribuição AleatóriaRESUMO
The effect of concurrent administration of antacids on the relative bioavailability of sotalol has been examined in five healthy volunteers. Each subject received an oral 160 mg dose after an overnight fast in four different experimental schedules. Venous blood samples were drawn 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, and 32 hours after the drug administration, and sotalol concentrations were determined fluorometrically. The results show that concurrent administration of calcium carbonate or aluminum hydroxide with sotalol has negligible pharmacokinetic consequences. The adsorption of sotalol onto magnesium hydroxide leads to somewhat decreased bioavailability but in long term use the phenomenon is not likely to be of clinical importance.
Assuntos
Antiácidos/farmacologia , Sotalol/metabolismo , Adsorção , Adulto , Feminino , Humanos , Técnicas In Vitro , Absorção Intestinal/efeitos dos fármacos , Masculino , Pessoa de Meia-IdadeRESUMO
1 The roles of the hepatic blood flow and the drug oxidizing enzyme system in eliminating oral propranolol and sotalol were studied in twelve subjects with biopsy proven liver parenchymal disease. 2 The apparent plasma clearance of propranolol was closely related both to the in vivo (antipyrine test) and in vitro (cytochrome P-450) indices of the activity of the hepatic mixed function oxidase system. 3 Propranolol clearance had also a clear relationship to the estimated liver blood flow. Altered flow was, however, suggested to be a minor factor when compared with changes in the enzyme system. 4 The elimination rate of sotalol had no correlation to the indices of hepatic drug metabolism or to the estimated liver blood flow. 5 It is concluded that both the deteriorated sinusoidal perfusion and the decreased mass of drug metabolizing enzymes may be responsible for the impaired elimination of oral propranolol in subjects with parenchymal liver disease.
